Hervolution can proudly welcome John Haurum, M.D., Ph.D. as a strategic advisor. John Haurum is a Non-executive Director in various European biotech companies, i.e. Synklino, Neophore, and Synact.
From 2012 – 2018, Haurum was the CEO of F-star in Cambridge, UK, where he built a successful biotech company that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue.
“John Haurum will be an amazing capacity for Hervolution. The biotech startup expertise he brings is an invaluable asset to the company,” says Peter J. Holst, CSO and interim CEO at Hervolution.
John Haurum is excited to bring his knowledge to Hervolution.
“The pre-clinical trials of Hervolution look very promising, and I look forward to following the continuous progression and growth. This has the potential to change the way we treat cancer,” says Dr. Haurum.
After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received his Ph.D. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up a position as Associate Professor at the Danish Cancer Society and completed his medical training.